370: Pharma sours on the U.K., plus biotech M...

Is the biotech industry truly out of its slump? Why are employers dropping coverage of weight loss drugs? And what will the hosts bake for the holidays? We discuss all that and more on this week's episode of "The Readout LOUD," the last episode of the year. We bring on Bruce Boot ...  عرض المزيد

How did Terns Pharmaceuticals and its “hodgepodge” pipeline grab attention at the American Society of Hematology conference? Is Eli Lilly’s new drug making people lose too much weight? And what, exactly, is the Trump administration’s plan for reforming the National Institutes of ...  عرض المزيد

Nicolai Tangen meets with David Ricks, CEO of Eli Lilly, for a discussion about the pharmaceutical giant's remarkable journey. At the forefront is Eli Lilly's breakthrough work with weight reduction drugs, which are showing promise far beyond their original ...

David Faber and Jim Cramer discuss the massive surge for stocks. Multiple reports emerging saying dexamethasone, a widely available drug, can help critically ill coronavirus patients. The treatment reportedly reduced Covid-19 deaths in hospitalized patients by up to one third. ...

Purdue Pharma’s owners in the Sackler family have agreed to a new $6.5 billion settlement to lawsuits over their role in the U.S. opioid crisis. This comes after a previous deal was rejected by the Supreme Court last year. We’ll break down the details of the settlement and wha ...

Carl Quintanilla and Jim Cramer led off the show by delving into the broadening market rally, as the S&P 500 and Nasdaq aim for a ninth consecutive day of gains. David Faber called into the show with reporting on Edgar Bronfman's bid to acquire Paramount Global. Eli Lilly CEO ...